Equillium (NASDAQ: EQ) exhibits high stock price volatility, a characteristic common among clinical-stage biotechnology equities whose market valuations fluctuate sharply based on binary clinical trial updates, regulatory announcements, cash runway disclosures, and broader macroeconomic shifts in small-cap healthcare sentiment.